Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies

Cristina Della Corte, Alessio Aghemo, Massimo Colombo

Abstract
Hepatocellular carcinoma (HCC) develops in the context of environmental risk factors like chronic viral hepatitis, diabetes and alcohol exposure, often associated to an increased risk of cirrhosis. Antiviral treatments that are effective to counteract hepatitis B and C may also attenuate the risk of tumor development. However, since hepatitis B-related carcinogenesis is promoted independently of the onset of cirrhosis, such antiviral treatments as nucleo(t)sime analogs can promote regression of cirrhosis, prevent clinical decompensation and variceal bleeding but not HCC. This means that in successfully treated patients with cirrhosis, HCC is often the consequence of their extended survival. In hepatitis C patients, a sustained virological response to interferon-based therapies can reduce the rate of HCC development, even in patients with cirrhosis who experience histological regression of their liver disease. Future therapies aimed at this endpoint in at risk populations should take into consideration pretreatment patient stratification for host, viral and environmental risk factors. In this context the recent discovery of single nucleotide polymorphisms involved in the immune system function and tumorigenesis, might permit enrollment of populations of patients enriched with HCC risk factors for targeted chemopreventive therapies. This could finally pave the way to personalized algorithms, as already seen in the diagnosis and treatment schemes for chemoprevention.

INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer in men and seventh in women, accounting for 7% of all cancers, and the third most common cause of cancer related death, worldwide[1]. HCC is characterized by peculiar biological and clinical features that may be relevant to primary and secondary prevention strategies. Indeed, up to 95% of all HCCs occur in the context of known and preventable risk factors, such as chronic viral hepatitis, alcohol abuse and cirrhosis (Table 1). Secondly HCC is one of the few cancers that can be diagnosed by radiological techniques, hence avoiding invasive diagnostic methods. Lastly, HCC is the only cancer that does not contraindicate patients to organ transplantation but actually benefits from liver transplantation in accurately selected patients. These rather unique features of HCC, in theory, could be used to implement therapeutic
and diagnostic measures to reduce or prevent the rate of HCC development in patients at risk, enforce surveillance programs in at risk populations aimed at early diagnosis and individualize treatment options based upon patient and tumor characteristics once the tumor has developed. Some of these points have been thoroughly investigated by clinical research studies and have led to significant advances in clinical practice that include the development of specific guidelines on surveillance protocols and on individualized treatment algorithms for HCC. Less successful have been attempts to design primary prophylaxis studies in at risk populations, such as those with hepatitis B virus (HBV) or hepatitis C virus (HCV), a fact that is especially worrisome as HCC arising in these patients still represents the core of the HCC epidemic in most countries. Indeed, chronic HBV and HCV infection affect roughly 400 and 200 million people, respectively, worldwide, and are the current leading causes of liver-related death and the main indication for liver transplantation in developed countries[2].

HCC RISK FACTORS

Hepatic disease status

HCC almost invariably occurs in a histologically abnormal liver, the mere existence of chronic liver disease representing a potential risk for the development of this tumor. Indeed, on the top of specific virus mechanisms that may be directly carcinogenic to the liver, chronic necro-inflammation and accumulation of reactive oxygen species contribute to carcinogenesis through chromosomal injury[3]. Cirrhosis, the end stage consequence of hepatic inflammation resulting in nodular transformation of the liver, is considered a premalignant condition, independently of etiology. Whether the association of cirrhosis with HCC reflects a long lasting exposure to carcinogenic agents capable of causing liver cell inflammation or a carcinogenic effect of disrupted lobular organization, is a matter of debate[6].

The prevalence of cirrhosis in persons with HCC is about 80%-90% in autopsied series worldwide, whereas approximately only 10%-20% of HCCs may be encountered in non-cirrhotic patients[3]. However, only a few non-cirrhotic patients with HCC have absolutely normal liver histology, as the majority show fibrosis stages that range from no fibrosis (F0) to septal (F2) and bridging fibrosis (F3) with necroinflammation, steatosis, and liver cell dysplasia[6-8].

In a detailed study from Japan involving 490 untreated patients with chronic hepatitis C, the HCC incidence per 100 person years increased with the stage of fibrosis at diagnosis, from 0.4 among patients with stage F0 or F1 to 1.5, 5.1 and 6.9 among those with fibrosis stages F2, F3 and F4, respectively[6,9]. The presence of large cell change[10,11], irregular regeneration of hepatocytes and macroregenerative nodules have been evaluated as morphologic predictors of HCC in cirrhosis independently of baseline disease[10-14].

Cirrhosis is not only driven by viral hepatitis but can also be the consequence of other conditions like hemorrhochromatosis, Wilson’s disease, antitrypsin deficiency, primary biliary cirrhosis, and autoimmune hepatitis[11]. Patients with cirrhosis stemming from genetic hemochromatosis have a 20-fold relative risk of developing HCC, compared to the general population, with an annual incidence of about 3%-4%[12]. In general, the risk of HCC in patients with cirrhosis increases in parallel to ageing, male gender, disease activity, degree of liver cell proliferation, presence of hepatobiliary phenotype on liver cells and serum level of alpha-fetoprotein. Patients with more advanced Child-Pugh scores are at higher risk of liver cancer, Child-Pugh class B/C patients having a 3-fold increased risk compared to Child Pugh A patients[13,17].

Viral factors

HBV: The annual incidence of HCC in patients with chronic hepatitis B, ranges from 2% to 5%, in strict correlation with the histological stage of the underlying liver disease, serologic status and geographic area[14]. Chronic HBV infection is commonly considered a primary risk factor for the development of HCC, exerting its prooncogenic properties through both indirect and direct mechanisms[16,27]. The indirect mechanisms are related to its propensity to induce continuous or recurrent phases of liver necroinflammation and to promote the progression of chronic hepatitis to cirrhosis, often preceding the development of HCC[24]. Most cases of HBV-related HCC (70%-90%) occur in patients with cirrhosis secondary to chronic necroinflammation, but HBV itself can cause HCC in the absence of cirrhosis through direct carcinogenic mechanisms that have been related to the capacity of HBV to integrate into the host’s genome and to produce proteins (X protein and truncated preS-S protein) with potential transforming properties[25].

In Europe, HBV-related HCC is associated with cirrhosis in the majority of patients[26,27], whereas this is not true in Asia and Africa where the tumor is common also among carriers with mild hepatic fibrosis, likely as a consequence of long standing infection that is often acquired perinatally[21,30].

HCC risk may be modulated by viral load[31-33], even when this predictor is measured years before tumor diagnosis, and can be modified also by serum hepatitis B e antigen (HBeAg) persistence and hepatitis B surface antigen (HBsAg) status[11,30-38].

Recently, it has been demonstrated that HCC may
also develop in Asian carriers with inactive hepatitis (i.e., persistently normal alanine transaminase and serum HBV DNA < 2000 IU/mL) [26,27,31,39] and HCC was also found to develop in a significant number of patients from 1 year to more than 10 years following spontaneous clearance of serum HBsAg, with a higher risk among patients who had HBsAg seroclearance after 50 years of age [40]. Other studies with sensitive amplification assays have shown that HBV DNA persists in serum or liver as an occult HBV infection, even following spontaneous serological recovery from transient HBV infection [HBsAg-negative status] [41].

The estimated incidence rates of HCC in subjects with chronic HBV infection in East Asian countries is 0.2 per 100 person-years in inactive carriers, 0.6 per 100 person-years for those with chronic HBV infection without cirrhosis, and 3.7 per 100 person-years for those with compensated cirrhosis; while in Europe/North America the HCC incidence rate was 0.02 per 100 person-years in inactive carriers, 0.3 per 100 person-years in subjects with chronic HBV without cirrhosis, and 2.2 per 100 person-years in subjects with compensated cirrhosis [42].

Male sex, positive family history and African origins are added risk factors for HCC development in HBV positive patients [28,30]. Genotype B of the HBV seems to be associated with lower rates of HCC development compared to genotype C of HBV [43-48], since it is characterized by anticipated HBeAg seroconversion, higher rates of sustained remission after HBeAg seroconversion, less active hepatic necroinflammation and slower progression to cirrhosis. Genotype A infections have a generally more favorable outcome than genotype D infections which predominate in the Mediterranean basin [49,50].

HCV: Chronic infection with HCV affects more than 170 million individuals, representing a major cause of morbidity and anticipated liver-related death in western countries and Japan. HCC is the dominant, first to appear complication of patients with long standing infection complicated by cirrhosis, which in fact is considered the main risk factor for HCC in patients with HCV infection, as only a minority of HCC cases develop in patients with mild-to-moderate HCV disease. Malignant transformation of hepatocytes occurs through a pathway of increased liver cell turnover, induced by chronic liver injury and regeneration in a context of inflammation and oxidative DNA damage [51] which facilitates the occurrence of genetic and epigenetic alterations that over decades can lead to the development of HCC. Still there are lines of evidence that support a direct role for HCV in cancer promotion [52]. Clinically this is supported by the incidence of HCC in HCV-related cirrhosis being higher than that reported in cirrhosis resulting from other liver diseases such as autoimmune hepatitis or metabolic syndrome [53]. Whether HCV genotype 1b produces a higher risk of HCC development compared to other HCV genotypes, is debatable, yet de facto reinforces the concept that HCV itself may promote HCC [54].

The HCV genome consists of a single stranded positive sense RNA of approximately 9.6 kb in length, that encodes a 327 kDa polyprotein that is processed into 10 mature structural and non structural viral proteins [55]. HCV proteins have been shown to impact on cell signaling, transcriptional modulation, transformation, apoptosis, membrane rearrangements, vesicular trafficking and translational regulation [56]. Four of the HCV gene products (core, NS3, NS4B and NS5A) show transformation potential in cell culture systems. Transgenic mouse models support HCV induced carcinogenesis, with transgenic lineages with high level liver specific expression of the core protein and transgenic mice for the two envelop proteins E1 and E2 developing HCC even in the absence of hepatic inflammation [56,57]. HCV can also induce endoplasmic reticulum (ER) stress, a homeostatic mechanism that regulates cellular metabolism and protein synthesis in response to perturbations in protein folding and biosynthesis [58]. Persistent ER stress may result in intra- and extra-cellular accumulation of DNA-damaging factors known to predispose cells to mutagenesis.

Human immunodeficiency virus: Human immunodeficiency virus (HIV) infection significantly increases the risk of liver-related morbidity and mortality, primarily because during the highly active antiretroviral therapy (HAART) era an important reduction in HIV-related complications has occurred, leading to the emergence of co-infection with HBV (6%-14%) and HCV (25%-30%) as hepatotoxic factors in addition to excessive alcohol consumption, non-alcoholic fatty liver disease and drug-induced liver injury [59].

While the MORTAVIC study in 2001 indicated HCC to be responsible for 25% of all liver deaths in HIV patients, in the HAART era there are studies showing HCC developing in co-infected patients to be more aggressive, to present at an earlier age and to less frequently be curable compared to HCC developing in HCV mono-infected patients. A direct oncogenic effect of the virus has therefore been hypothesized by some [60,61].

Environmental risk factors
Alcohol: Chronic consumption of more than 80 g of ethanol per day for more than 10 years increases the risk of HCC by approximately 5-fold; in women even smaller quantities of alcohol consumption (10 g/d) are associated with a significant (24%) increase of HCC risk [62]. Alcohol abuse in patients with chronic hepatitis C doubles the risk for HCC, due to a synergism between alcohol and hepatitis C in anticipating HCC onset or causing more severe histological tumor patterns. In a HCC cohort in Austria, alcoholic liver disease was the likely cause of HCC in 35% of subjects [63], whereas in the United States, the hospitalization rate for HCC related to alcoholic cirrhosis is (8-9)/100 000 people per year compared to about 7/100 000 people per year for hepatitis C [64]. Heavy alcohol consumption can lead to liver damage by direct liver cell injury and generation of toxic metabolites, thereby
transforming the liver in a mitogenic and mutagenic environment. This not only causes development of liver fibrosis and cirrhosis\cite{85,86}, but also increases conversion of pro-carcinogens to carcinogens through oxidation and metabolism of ethanol in the liver\cite{87}. Acetaldehyde and oxygen free radicals deriving from ethanol metabolism may also directly induce cell damage by initiating peroxidation of membrane lipids, through oxidative stress\cite{88}.

**Metabolic syndrome:** Diabetes is an independent risk factor for HCC; a recent surveillance epidemiology and end results based re-analysis has shown a 2-3-fold increase in the risk of HCC, regardless of the presence of other major risk factors\cite{89}. Further evidence that obesity and diabetes are either jointly or independently associated with an increased risk of HCC is provided by an Italian case control study and by several large-scale epidemiological studies, that have associated the overweight and obesity pandemic in the general population with an increase in HCC risk\cite{90}.

In a cohort of 900 000 American adults, the risk of dying from liver cancer was 4.5 times higher in men with a body mass index of 35 kg/m² or above compared to men with a normal body mass index (18.5-24.9 kg/m²)\cite{91}. A meta-analysis of case control and cohort studies concluded that the relative risk of liver cancer was 1.17 for overweight subjects and 1.89 for obese patients\cite{92}. These and other studies contribute to the increased recognition of non-alcoholic steatohepatitis (NASH) as a cause of cirrhosis and HCC, with many patients progressing to liver cancer without histological evidence of advanced fibrosis or cirrhosis\cite{93-95}.

A yearly cumulative incidence of HCC in 2.6% of patients with NASH compared to 4.0% of those with HCV over a median follow-up time of 3.2 years was also demonstrated in patients referred for liver transplant evaluation at Cleveland Clinic in Ohio\cite{96}. Interestingly, this cohort of patients, older age at diagnosis of cirrhosis and any alcohol consumption were independently associated with the development of HCC in a NASH-cirrhosis population, suggesting that alcohol intake, even in socially accepted amounts, may potentially increase the risk of HCC development both in NASH- and HCV-cirrhotic patients.

The precise mechanisms through which metabolic factors drive HCC development are complex and beyond the scope of this article; however, major systemic and liver specific molecular mechanisms like insulin resistance, hyperinsulinemia, increased expression of tumor necrosis factor signaling pathways and direct lipotoxicity are major players in the development of HCC.

**Host-related risk factors**

**Age and sex:** Among host factors, older age and male sex have consistently been found in longitudinal studies to be associated with an increased risk of HCC among persons with cirrhosis of different etiologies, with the caveat, however, that age might reflect longer duration of hepatic disease\cite{76-79}.

In patients with cirrhosis, there is a striking gender imbalance in HCC incidence, with a predominance for males independently from geographic area, etiologic factors and ethnicity with a male to female ratio between 2:1 to > 4:1 being reported across studies\cite{97}. While male preponderance could just reflect the greater incidence of viral hepatitis and alcohol-related disease in males, it could also be related to hormonal diversity. High serum levels of testosterone have been associated with increased HCC risk in nested case-control studies of HBV carriers in Taiwan and Shanghai\cite{98}, while a cross-sectional study in male veterans with chronic HCV in the United States associated higher total serum levels of testosterone with risk of advanced hepatic fibrosis and inflammatory activity, without examining the association with HCC\cite{98}.

Among the complex molecular mechanisms behind gender disparities in HCC, estrogens may play a role in increasing interleukin-6 (IL-6) production and modulation of gene expression through FOXA transcription factors that have been shown to prevent HCC development in experimental models. However, more data are still needed to define the implication of sexual hormones in the molecular pathogenesis of HCC\cite{99}.

**Single nucleotide polymorphisms associated with HCC**

Genetic host factors play an important role in HCC development. The most common form of genetic variation between individuals is single nucleotide polymorphisms (SNPs) which are a variation in a DNA base at a particular nucleotide locus. A common SNP is defined by having a minor allele frequency of at least 5%. In studies designed with a “candidate gene approach”, a limited number of biologically plausible SNPs were tested. The starting hypothesis is that a given variant in a specific gene involved in a pathway that influences HCC development can sufficiently alter either protein function or expression, and result in the modulation of cancer risk. Another approach to study genetic factors is through “genome wide association studies” (GWAS). These studies are by definition “hypothesis free”, and compare allele/genotype frequency of common variants between cases and unaffected controls and test 100 000 of tag SNPs reflecting common genetic variations across the entire human genome. To reach GWAS significance (P value = 0.05/number of SNPs tested) a P value in the order of $<10^{-8}$ is typically required\cite{84}.

To identify susceptible genetic variants for HCV- and HBV-related HCC many genetic association studies have been conducted; unfortunately most publications suffer from major methodological drawbacks because of their case-control, retrospective and single center design, mainly involving selected Asian populations. This minimizes the potential importance of ethnic diversity, calling for external validation in populations of different ancestry before effectively translating results to clinical practice. Prospective cohort studies conducted in large homogeneous populations with sufficient number of events
Given the relatively small number of cases in the GWAS phase, the statistical power to detect an effect caused by this SNP was only 50%, compared to the 80% recommended to detect an association of the expected effect size.

Factors of selection bias cannot be excluded because 11.6% of the “genotyping cohort” had > 60 g alcohol consumption per day, secondly because 16.5% of the controls received antiviral treatment before enrolment.

The viral infection status of controls was not ascertained with the consequence that there might be hypothetical cases with chronic liver disease.

| Study | Patients | SNP locus | Strength | Comment |
|-------|----------|-----------|----------|---------|
| Kumar et al[93] | 1730 HCV neg | MICA | OR 1.3 | This study considers HCV-negative individuals as the controls, hence it isn’t useful in distinguishing HCC high risk population among HCV-related cirrhotic patients. |
| Miki et al[94] | 2390 CHC-HCC | DEPDC5 | OR 2.2 | Given the relatively small number of cases in the GWAS phase, the statistical power to detect an effect caused by this SNP was only 50%, compared to the 80% recommended to detect an association of the expected effect size. |
| Zhang et al[95] | 1790 CHB-HCC | KIF1b | 0.6 | Confounding non-genetic HCC risk factors cannot be ruled out in multivariate analysis. |
| Chan et al[96] | 825 CHB-HCC | DLCI | 1.3 | Factors of selection bias cannot be excluded because 11.6% of the “genotyping cohort” had > 60 g alcohol consumption per day, secondly because 16.5% of the controls received antiviral treatment before enrolment. |
| Clifford et al[97] | 386 HCC | MHC II | $p1 \times 10^{-15}$ | The viral infection status of controls was not ascertained with the consequence that there might be hypothetical cases with chronic liver disease. |

Table 2  Genetic associations with hepatocellular carcinoma at genome wide association studies level

| Study | Patients | SNP locus | Strength | Comment |
|-------|----------|-----------|----------|---------|
| Kumar et al[93] | 1730 HCV neg | MICA | OR 1.3 | This study considers HCV-negative individuals as the controls, hence it isn’t useful in distinguishing HCC high risk population among HCV-related cirrhotic patients. |
| Miki et al[94] | 2390 CHC-HCC | DEPDC5 | OR 2.2 | Given the relatively small number of cases in the GWAS phase, the statistical power to detect an effect caused by this SNP was only 50%, compared to the 80% recommended to detect an association of the expected effect size. |
| Zhang et al[95] | 1790 CHB-HCC | KIF1b | 0.6 | Confounding non-genetic HCC risk factors cannot be ruled out in multivariate analysis. |
| Chan et al[96] | 825 CHB-HCC | DLCI | 1.3 | Factors of selection bias cannot be excluded because 11.6% of the “genotyping cohort” had > 60 g alcohol consumption per day, secondly because 16.5% of the controls received antiviral treatment before enrolment. |
| Clifford et al[97] | 386 HCC | MHC II | $p1 \times 10^{-15}$ | The viral infection status of controls was not ascertained with the consequence that there might be hypothetical cases with chronic liver disease. |

89% HBV or HCV viral infection; 76% HBV or HCV viral infection; 3 Not known viral status. CHC: Chronic hepatitis C; CHB: Chronic hepatitis B; GWAS: Genome-wide association study; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; SNP: Single nucleotide polymorphism.

during follow-up require a long time to be conducted and therefore are still scarce.

The genetic regions found to have a significant statistical association with HCC at a GWAS level in chronic hepatitis C patients are the 5’ flanking region of MICA (the MHC class I polypeptide-related sequence A gene, on chromosome 6p21.33) which is essential for direct immune system functions[83] and isoform1 of the DEPDC5 locus on chromosome, where deletion of the region containing DEPDC has been reported in malignant brain glioblastomas[95]. Also the MHC class II locus presenting antigen to CD4+ (helper) T cells contains three variants strongly associated with HCC, probably related to altered MHC class II proteins that result in an ineffective T-cell response[87]. KIF1B was identified as a new susceptibility locus for HCC in chronic HBV carriers; the loss of heterozygosity on this locus is a common genetic lesion in a broad range of human cancers[89]. Variations at chromosome 8p12 may also promote HCC in patients with HBV and risk-associated 8p12 SNPs or haplotypes might have an interacting effect on the DLC1 locus (Deleted in Liver Cancer 1), which becomes more susceptible to deletion or chromosomal loss[90] (Table 2).

In the HALT-C study cohort a significant association between a polymorphism on epidermal growth factor gene and HCC was detected in a retrospective case-control study, by the use of a candidate gene approach[90]. With this same approach in HBV patients many other genes involved in immune and tumorigenesis processes were found to be significantly associated with HCC development, among these cytotoxic T-lymphocyte antigen 4 gene[91], the promoter region of MCM7 gene and the enhancer II (Enh II)[92], basal core promoter, and precore regions of HBV[93].

Still the SNPs identified so far only partly explain the overall variability in HCC susceptibility as they carry a rather low risk ratio for HCC development, have been mostly assessed in well selected patients where HCC tissue was obtained following surgical resection and therefore at this moment do not permit prediction at the individual and population level. Whole genome sequencing analysis of HCCs nodules are promising approaches; recently Fujimoto et al[94] have identified etiological diverse specific mutation patterns and several mutation of chromatin regulators in 27 HCCs.

In 2008 the International Cancer Genome Consortium was launched with the purpose to coordinate large-scale cancer genome studies in tumors from 50 cancer types and/or subtypes that are of main importance across the globe, including HCC. Systematic studies of more than 25 000 cancer genomes at the genomic, epigenomic and transcriptomic levels are needed to reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies. Hopefully in the not so distant future, partial or full cancer genomes will routinely be sequenced as part of the clinical evaluation of cancer patients and as part of their on-going clinical management[95].

**CHEMOPREVENTION**

Although all host related HCC risk factors are unmodifiable and at this moment do not call for any preventive measures, environmental and viral factors can either be prevented, suppressed or in some cases cured by effective treatments[90]. For viral hepatitis B and C and for HIV infection the question is whether the effective antiviral treatments that have been developed in the last decade to treat patients with virus induced liver disease can be considered chemopreventive approaches for HCC in parallel.

**HBV**

Prevention of HCC in patients with a sustained suppression of HBV following interferon or NUC therapy is far from being convincingly demonstrated, especially since this dramatic and life threatening complication in most...
patients occurs many decades after viral infection and many years after diagnosis of hepatitis.

The benefits of a virological suppression in patients with cirrhosis are easier to evaluate as these patients are the closest to developing hepatitis-related complications. Several studies have shown that HBV patients who achieve a virological response to lamivudine in some cases still develop hepatocellular carcinoma (HCC) as the only complication. LAM: Lamivudine; ETV: Entecavir; RCT: Randomized controlled trial.

![Figure 1 Hepatocellular carcinoma rates in nucleos(t)ide analogs-naive cirrhotic patients with long-term response. Several studies have shown that hepatitis B virus patients who achieve a virological response to lamivudine in some cases still develop hepatocellular carcinoma (HCC) as the only complication. LAM: Lamivudine; ETV: Entecavir; RCT: Randomized controlled trial.](image1)

With regards to HCV there is conclusive evidence that an sustained virological response (SVR) following interferon (IFN) based therapies can reduce the rate of HCC development, independently of fibrosis stage. This has been repeatedly shown both by studies in Caucasian patients as well as in patients from Asia. Interestingly an SVR does not completely negate the risk of HCC, as a small group of patients will still develop HCC in the long term follow-up period, although the annual rate is extremely low and reduced compared to non-responders or untreated patients. In an Italian study on 920 patients with compensated cirrhosis who received IFN monotherapy and who were followed-up for a median period of 96 mo after treatment completion, Bruno et al. found that SVR patients had significantly lower rates of HCC (0.66 vs 2.10 per 100 person-years) and liver-related death (0.19 vs 1.44 per 100 person-years, P < 0.001) compared to those with treatment failure. Similar findings were also reported by Cardoso et al. in a study that analyzed 307 patients with bridging fibrosis or cirrhosis followed-up for 3.5 years after the end of treatment. The authors found significantly lower incidence rates per 100 person-years of liver-related complications, liver-related deaths, and HCC in SVR than in non-SVR patients.

![Figure 2 Cumulative incidence of hepatocellular carcinoma in patients with cirrhosis stratified by sustained virological response. Studies in Caucasian patients as well as in patients from Asia have repeatedly shown that a sustained virological response (SVR) following interferon-based therapies can reduce the rate of hepatocellular carcinoma development in hepatitis C virus related cirrhosis. HCC: Hepatocellular carcinoma.](image2)
before suggesting PegIFN maintenance therapy as an effective chemoprevention strategy in HCV cirrhotics; still they provide important clues and directions for future studies. Indeed, it shows patients enrolled in chemoprevention studies need to be stratified for risk factors at baseline; in this particular case enrolling patients with different disease severity stage might have precluded observation of a protective effect of low dose PegIFN on HCC development. Secondly it suggests that conducting studies on high risk rather than medium risk patients might provide more clinically meaningful data.

**HIV**

Although a detailed discussion about the effect of antiviral therapy in HIV positive patients on HCC development is beyond the purpose of this study, convincing evidence has been provided that HCC incidence is rising amongst the HIV positive population receiving HAART, almost exclusively in patients with concomitant HCV or HBV infection. The main explanation behind these findings is probably the increased longevity obtained by effective antiviral treatment in this population of patients. An investigation of the Swiss HIV cohort assessed that latest CD4þ cell count and CD4þ cell count percentage were significantly associated with HCC, but no association between HAART use and HCC risk was detected. Similarly, Sulkowski et al. reported that HCC occurred in many patients despite the use of effective HAART for a median of more than 7 years.

Thus, antiretroviral therapy is unlikely to modify the risk of HCC in HCV-infected patients in whom the risk of cancer is driven by HCV-related cirrhosis and where antiretroviral therapy is also known to have some direct hepatotoxic effects which are worsened by co-infection with HBV or HCV, raising the possibility that HAART per se might hasten the progression to cirrhosis and hence HCC. However the role of HAART on HCC development is controversial because its ability to preserve immune system functions could in theory provide a putatively more active anti-tumor response, since once HCC has developed, chronically low CD4+ and CD8+ lymphocyte counts may result in more rapid growth and spread of disease.

**CONCLUSION**

HCC develops in the context of readily identifiable environmental risk factors, first of all HBV and HCV, a fact that in theory should enable for successful primary prophylaxis. There are solid treatment endpoints that allow hepatologists to determine the efficacy of an antiviral regimen and its ability to positively modify both the natural course of the disease as well as to reduce the risk of HCC development. Unfortunately in patients with chronic HBV and HCV infection tumor prevention is an end point quite difficult to assess in patients with early, mild hepatitis whereas it can only partially be achieved in patients with established cirrhosis given they are at higher risk of liver cancer.
In these patients there is increasing need to improve diagnosis rate, ensure equal access to antiviral therapies and develop well tolerated therapies that will finally allow most, if not all, patients with viral hepatitis to benefit from effective antiviral treatment. In fact it is estimated that as few as 35% of patients with chronic HBV and only 25% of HCV patients are aware of their disease in developed countries.[126] Moreover in Europe and the United States, even if patients are diagnosed correctly only 1%-16% of HBV and HCV patients are estimated to receive treatment.[127][129]

This highlights that one of the key issues for therapies aimed at HCC chemoprevention is to broaden access to therapies by containing costs and increasing disease awareness, or eventually concentrate treatment in those more at risk of HCC development. Performing prospective studies where patients are stratified according to complex models of “genomic risk prediction” that incorporate various panels of specific SNPs, is undoubtedly a bold and possibly unreachable goal, but still it could lead to individualized chemoprevention strategies in the future, while reducing the number of patients needed to be enrolled into chemoprevention studies to assess efficacy of a treatment regimen. Until this is reached, secondary prevention through surveillance of risk populations aiming at early diagnosis is the only approach to improve treatment and survival of patients with HCC.

ACKNOWLEDGMENTS

Financial disclosure: Alessio Aghemo, MD; Grant and research support: Roche, Gilead Sciences; Speaking and Teaching: Roche and Janssen; Travel support: BMS, Glaxo Smith-Kline, Bayer, Janssen and Roche; Financial disclosure: Massimo Colombo, MD; Grant and research support: Merck, Roche, BMS and Gilead Science; Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science, Tibotec, Vertex and Achillion; Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead Science and Vertex; Cristina della Corte, MD: nothing to disclose.

REFERENCES

1. IARC. Available from: URL: http://www.depm.iarc.fr. Accessed November 1, 2011
2. EASL-EORTC. Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. J Hepatol 2012; 56: 908-943
3. Fattovich G, Stroffolini T, Zagni I and Donato F. Cirrhosis and hepatocellular carcinoma. Gastroenterology 2004; 127: S35-S50 [DOI: 10.1053/j.gastro.2004.09.014]
4. Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-S53 [PMID: 12591185]
5. Simonetti RG, Cammà C, Fiorello F, Politi F, D’Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991; 36: 962-972 [PMID: 1649041]
6. Bralet MP, Régimbeau JM, Pineau P, Dubois S, Loas G, Degos F, Valla D, Belghiti J, Degott C, Terris B. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 1991; 14: 200-204 [PMID: 1915724]
7. Chiesa R, Donato F, Tagger A, Favret M, Riberio ML, Nardi G, Gelatti U, Bucella E, Tomasi E, Portolani N, Bonetti M, Bettini L, Pelizzari G, Salmi A, Savio A, Garatti M, Callea F. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000; 9: 213-216 [PMID: 10698484]
8. Grando-Lemarie V, Guettier C, Chevret S, Beauprè M, Trinchet JC. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol 1999; 31: 508-513 [PMID: 10488711]
9. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, INoue O, Yano M, Tanaka M, Fujiyama S, Nishi-guchi S, Kuroki T, Imaizeki F, Yokosuka O, Kinoyama S, Yamada G, Omata M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHT Study Group: Inhibition of Hepatocarcino genesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181 [PMID: 10428733 DOI: 10.1186/1471-229X-12-139]
10. Degos F, Christidis C, Ganne-Carrièe N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beauprè M, Chevret S. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2008; 57: 131-136 [PMID: 18612275]
11. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, Leandro G, Servida E, Podda M. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995; 108: 812-817 [PMID: 7875483]
12. Ganne-Carrièe N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, Deny P, Trinchet JC, Callard P, Guettier C, Beauprè M. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996; 23: 1112-1118 [PMID: 8621142]
13. Shibata M, Morizane T, Uchida T, Yamagami T, Onozuka Y, Nakano M, Mitamura K, Ueno Y. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998; 351: 1773-1777 [PMID: 9635999]
14. Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, Oldani S, Cotichini R, Roncalli M. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39: 208-214 [PMID: 12875817]
15. Elimb erg M, Hultcrantz R, Ekborn A, Brandt L, Olsson S, Olsson R, Lindgren S, Lööf L, Stöl P, Wallerstedt S, Almér S, Sandberg-Gertzen H, Asking J. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125: 1733-1741 [PMID: 14724826]
16. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effective ness analysis. Gut 2001; 48: 251-259 [PMID: 1156649]
17. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1999; 76: 968-974 [PMID: 9328611]
18. Fattovich G, Brollo L, Giustina G, Noventa F, Pontissio P, Alberti A, Realdi G, Ruol A. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294-298 [PMID: 2013423]
19. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Della Corte C et al. Individualized HCC risk
Nguyen CV, Rowe WL, Sharma S, Wu G, Yan C, Zhang H, Chung YH, Kim JA, Park NH, Song IH, Buethow K. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 2010; 52: 2034-2043 [PMID: 21105178 DOI: 10.1002/hep.23383].

88 Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, Ma F, Huang W, Yu L, Yue W, Wang Z, Li P, Zhang Y, Liang R, Wei Z, Cui Y, Xie W, Cai M, Yu X, Yuan X, Xia X, Zhang X, Yang H, Qiu W, Yang J, Gong F, Chen M, Shen H, Lin D, Zeng YX, He F, Zhou G. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42: 755-758 [PMID: 20276096 DOI: 10.1038/ng.638].

89 Chan KY, Wong CM, Kwan JS, Lee JM, Cheung KW, Yuen MF, Lai CL, Poon RT, Sham PC, Ng IO. Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6: e28798 [PMID: 22174901].

90 Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JF, O'Brien TR, Dieresteg JL, Tanabe KK, Chung RT. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 141-149 [PMID: 21440548].

91 Gu X, Qi P, Zou F, Ji Q, Wang H, Dou T, Zhao Y, Gao C. +49K & gt; A: A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010; 71: 83-87 [PMID: 19778566 DOI: 10.1016/j.humimm.2009.09.353].

92 Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu J, Pan S, Chen J, Shen H, Hu Z. A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One 2012; 7: e32230 [PMID: 22393390].

93 Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, Shih WL, Chen PJ, Liaw YF, Chen CJ. Temporal relationship between hepatitis B virus enhancer II basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 2008; 57: 91-97 [PMID: 17502344].

94 Fujiimoto A, Totoki Y, Abe T, Borovich KA, Hosaoda F, Nguyen HH, Akioi M, Hosono N, Kubo M, Miyia S, Arai Y, Takahashi Y, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Aihiro K, Ohdan H, Gotoh K, Ishikawa O, Arizumi S, Yamamoto M, Yamada T, Chayama K, Koseuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagama H. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012; 44: 766-710 [PMID: 22634756].

95 Hudson TJ, Anderson W, Arzeto A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Erola I, Gerhard DS, Gottmacher A, Guyer M, Hemsley FM, Jennings KL, Kerr D, Klatt P, Kolar P, Kusada J, Laney H, Penn R, Remacle J, Schaefer AJ, Schajer A, Shibata T, Stratton MR, Vockley JG, Waddell NJ, Wilson PJ, McPherson JD, Lowrance WW, Davis C, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol 2012; 57: 1326-1335 [PMID: 22705479].
Virological suppression does not prevent the development of hepatocellular carcinoma in HBsAg-negative hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. J Gastroenterol Hepatol 2011; 36: 34-40.

Koga H, Ide T, Oho K, Kuwahara R, Hino T, Ogata K, Hisa M, Takehara T. Long-term effect of lamivudine treatment on hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012; 47: 577-585. [PMID: 22231575]

Kogawa M, Hiramatsu N, Ose T, Yukishii T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsuni K, Kato T, Kasahara A, Ito S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012; 47: 577-585. [PMID: 22231575]

Kovacs K, Deprez D, Pichard A, Fontaine H, Pol S. Brief communication: the relationship of IL28B with response to pegylated interferon-alpha in chronic hepatitis C patients with advanced fibrosis. J Hepatol 2007; 47: A20.

Kurokawa M, Hiramatsu N, Ose T, Yukishii T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsuni K, Kato T, Kasahara A, Ito S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012; 47: 577-585. [PMID: 22231575]

Koga H, Ide T, Oho K, Kuwahara R, Hino T, Ogata K, Hisa M, Takehara T. Long-term effect of lamivudine treatment on hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012; 47: 577-585. [PMID: 22231575]

Lamertoni D, Galli M, Di Cesare F, Ferri S, De Puario A, Gatti P, Belli G, Brunetto MR, Andreoletti M, Colli A, Fasano M, Santantonio T, Tagliaventi A, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuzzi S, Almasio PL. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587. [PMID: 17326216]

Lancaster CR, Fluckiger D, Mientjes M, Candea V, Vaudaux B, Calvet X, Taurin P, Chastang T, Autran B, Virelizier JL, Schiffmann ML, Everson GT, Lindsay KL. Incidence of hepatocellular carcinoma in chronic hepatitis C patients. J Hepatol 2004; 41: 958-994. [PMID: 15767158]

Lamperti P, Vignani M, Sofredini F, Rachetti F, Menolà E, Franchis R, Colombo M. Six years of on demand LAM ADV combination therapy significantly reduces the development of cirrhosis in patients with chronic hepatitis B. Hepatology 2007; 45: 655-665.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee JH, Yoo JH, Park HW, Moon DH, Park YH, Park MH, Kim TH, Shin J, Chung YE. A meta-analysis of lamivudine monotherapy in chronic hepatitis B patients with cirrhosis. Hepatol Res 2007; 37: 503-509. [PMID: 17599992]

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.

Lee J, Youn JJ, Kim H, Park H. The anti-tumor effect of L-asparaginase against hepatocellular carcinoma. J Hepatol 2011; 55: 129-135.
JL. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. *N Engl J Med* 2008; 359: 2429-2441 [PMID: 19052125 DOI: 10.1056/NEJMoat0707615]

119 Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. *Gastroenterology* 2011; 140: 1990-1999 [PMID: 21419770]

120 Afdhal N, Levine R, Brown R. Colchicine versus peginterferon alfa-2b long-term therapy: results of the 4 year COPILOT trial (oral presentation). Proceedings of 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan, Italy

121 Aghemo A, Colombo M. Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens. *J Hepatol* 2012; 56: 276-278 [PMID: 21782763 DOI: 10.1016/j.jhep.2011.05.034]

122 Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. *Gastroenterology* 2011; 140: 840-849, quiz e12 [PMID: 21129375]

123 Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, Rauch A, Probst-Hensch NM, Bouchardy C, Levi F, Franceschi S. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. *AIDS* 2008; 22: 2135-2141 [PMID: 18832877]

124 Sulkowski M. Hepatocellular carcinoma in HIV-infected patients comes of age: The convergence of epidemiology and treatment effectiveness. *J Hepatol* 2009; 50: 655-658 [PMID: 19243854 DOI: 10.1016/j.jhep.2009.01.009]

125 MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. *World J Gastroenterol* 2008; 14: 1657-1663 [PMID: 18355996 DOI: 10.3748/wjg.14.1657]

126 Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single-topic conference on “Chronic viral hepatitis—strategies to improve effectiveness of screening and treatment”. *Hepatology* 2012; 55: 307-315 [PMID: 22105599]

127 Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. *Hepatology* 2009; 50: 1750-1755 [PMID: 19824079]

128 Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, London WT, Block TM. Is chronic hepatitis B being undertreated in the United States? *J Viral Hepat* 2011; 18: 377-383 [PMID: 21143343]

129 Lettmeier B, Mühlberger N, Schwarzar R, Sroczynski G, Wright D, Zeuzem S, Siebert U. Market uptake of new antiviral drugs for the treatment of hepatitis C. *J Hepatol* 2008; 49: 526-536 [PMID: 18682313]

Della Corte C et al. Individualized HCC risk